Alnylam Pharmaceuticals Inc ALNY
(Start of Section)(Start of Section)Laatste Koers
145,79
Verandering 1 Dag
1,38|0,96%
Per 22-04-2024
08:00:05 EDT | USD
Minimaal 15 minuten vertraagd.
(Start of Section)| Bid/Offers | Laagste - hoogste dag | Volume | 90d Ave Vol | Mkt Kap |
|---|
| 141,00 - 155,48 | 143,69 - 147,90 | 2 | 843.712 | 18,44Bil |
| Laatste slotkoers | Laagste - hoogste koers van de afgelopen 52 weken | Koers-winst | Opbrengst % | ISIN |
|---|
| 144,41 | 143,50 - 218,88 | - | - | US02043Q1076 |
(Start of Section)Alnylam Pharmaceuticals Inc Koers
| 2021 | 2022 | 2023 |
|---|
| Meer... |
| Inkomsten | 844,29 | 1.037,42 | 1.828,29 |
|---|
| Exploitatie-inkomsten | -708,65 | -785,07 | -282,18 |
|---|
| Netto-inkomsten | -852,82 | -1.131,16 | -440,24 |
|---|
| Basis-EPS | -7,20 | -9,30 | -3,52 |
|---|
| Gem. uitstaande verwaterde aandelen | 118 | 122 | 125 |
|---|
| Vlottende activa | 2.808,58 | 2.692,25 | 2.982,70 |
|---|
| Langlopende activa | 834,73 | 854,11 | 847,18 |
|---|
| Totaal activa | 3.643,30 | 3.546,36 | 3.829,88 |
|---|
| Kortlopende verplichtingen | 695,71 | 767,92 | 967,79 |
|---|
| Totaal verplichtingen | - | - | - |
|---|
| Totaal eigen vermogen | 588,20 | -158,22 | -220,64 |
|---|
| Bedrijfscashflow | -641,69 | -541,27 | 104,16 |
|---|
| Investeringsuitgaven | -76,37 | -72,06 | -62,21 |
|---|
| Vrije cashflow | -718,07 | -613,33 | 41,95 |
|---|
In miljoenen, behalve "Basic EPS". Valuta is USD.
(Start of Section)Bedrijfsprofiel
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Sector
GezondheidszorgIndustrie
BiotechnologieStijl aandelen
Midden groeiEinde boekjaar
decemberWerknemers
2.100| Meer... |
| Koers-winst laatste 12 maanden | -41,03 |
|---|
| Koers/Boekwaarde | -82,76 |
|---|
| Koers/omzet laatste 12 maanden | 9,87 |
|---|
| Inkomstengroei (3 jaar gem) | 54,80 |
|---|
| Groei Winst per aandeel (3 jaar gem) | - |
|---|
| Exploitatiemarge % laatste 12 maanden | -15,43 |
|---|
| Nettomarge % laatste 12 maanden | -24,08 |
|---|
| ROE laatste 12 maanden | - |
|---|
| Schuld/eigen vermogen | - |
|---|
| Voorafgaande | Laatste |
|---|
|
| Declaratie datum | w.l.t. | w.l.t. |
|---|
| Ex-Div | w.l.t. | w.l.t. |
|---|
| Betaald | w.l.t. | w.l.t. |
|---|
| Bedrag | 0,00 | 0,00 |
|---|
